- Women Against MS Luncheon Committee Member Tina Brown Finds New Ways to Advocate for Holistic HealthPosted 1 week ago
- Programs in the Classroom Provide New Way of Fighting HungerPosted 1 week ago
- Animal ArtPosted 2 weeks ago
- Gabriel’s Angels: Pets Helping KidsPosted 2 weeks ago
- The Rebirth of Israeli Fashion House, MaskitPosted 2 weeks ago
- Office Doors: Jennifer JostPosted 2 weeks ago
Colleen’s Dream Grants $450K to TGen for Ovarian Cancer Drug Clinical Trial
Colleen’s Dream, a Scottsdale-based nonprofit that raises funds to support ovarian cancer research, has awarded Translational Genomics Research Institute $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment.
“The research being done at TGen is some of the most exciting we’ve ever seen,” said Nicole Cundiff, CEO of Colleen’s Dream Foundation. “Whether the drug they developed leads to another amazing discovery, or it becomes a first line ovarian cancer treatment, we truly believe what they’re doing will move the needle and we couldn’t be more proud to support an institute located here in Arizona.”
TGen’s research with a team of collaborators has led to the discovery of a gene mutation that can lead to an aggressive ovarian cancer.
One drug, seclidemstat, which was developed by Salarius Pharmaceuticals of Houston and has been evaluated by TGen, aims to restore balance within the gene and has shown promising preclinical results in ovarian cancers, and is even being clinically evaluated in other cancers driven by similar genetic imbalances.
“Our partnership with Colleen’s Dream has been critical for driving our translational research toward clinical impact,” said Dr. Will Hendricks, an assistant professor in TGen’s Integrated Cancer Genomics Division. “We look forward to building on preclinical studies of epigenetic anti-cancer drugs that have identified seclidemstat as a promising lead for ovarian cancer treatment.”
Colleen’s Dream focuses on raising funding to improve treatment of ovarian cancer and to provide reliable early detection. No early detection test currently exists, which is one of the leading factors as to why it is the deadliest gynecological cancer.